First Dr Reddy’s, then Hikma, then Teva, now Apotex. The Canadian firm is the latest generics manufacturer to file an antitrust lawsuit against Amarin, accusing the originator of an anticompetitive scheme to “delay, hinder, and frustrate robust generic competition” to its Vascepa (icosapent ethyl) purified fish oil brand by “locking up” the supply of the brand’s active pharmaceutical ingredient.
“For Amarin, it is Vascepa or bust. The company has no other products and no meaningful pipeline behind Vascepa,” Apotex...